Edgewise ups R&D spending as pharma firm focuses on cardiovascular pipeline
Edgewise spent more on research and development as the Boulder firm moves from muscular-dystrophy drug candidates to cardiovascular therapies.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Edgewise Therapeutics has clarified its relationship with a clinical researcher who recently received a warning…
-
Edgewise Therapeutics Inc., (Nasdaq: EWTX), a Boulder-based muscle-disease biopharmaceutical company, maintained a strong cash balance…
-
Edgewise Therapeutics plans to sell nearly 10 million shares of its common stock at $20.13,…
-
Edgewise Therapeutics has received orphan drug status in Europe for one of its drugs.
